Loading...
Citius Oncology, Inc.
CTOR•NASDAQ
Healthcare
Drug Manufacturers - General
$1.97
$0.02(1.03%)
Citius Oncology, Inc. (CTOR) Financial Performance & Income Statement Overview
Review Citius Oncology, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-69.72%
↓ 69.72%
Net Income Growth
-66.56%
↓ 66.56%
Operating Cash Flow Growth
0.00%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-34.03%
↓ 34.03%
ROIC
-17.92%
↓ 17.92%
Citius Oncology, Inc. (CTOR) Income Statement & Financial Overview
Review Citius Oncology, Inc.'s (CTOR) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $1.26M | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.13M | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $6.39M | $0.00 | $0.00 | $0.00 |
| Total Costs & Expenses | $6.39M | $0.00 | $0.00 | $0.00 |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA | -$6.39M | $0.00 | $0.00 | $0.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$6.39M | $0.00 | $0.00 | $0.00 |
| Income Before Tax | -$6.39M | $0.00 | $0.00 | $0.00 |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $264240.00 | $6813.00 | $4773.00 | $4836.00 |
| Net Income | -$6.66M | $0.00 | $0.00 | $0.00 |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.09 | $0.00 | $0.00 | $0.00 |
| Diluted EPS | -$0.09 | $0.00 | $0.00 | $0.00 |
| Weighted Avg Shares Outstanding | $71.55M | $71.55M | $66.53M | $66.53M |
| Weighted Avg Shares Outstanding (Diluted) | $71.55M | $71.55M | $66.53M | $66.53M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan